Inhibition of insulin‑like growth factor 1 signaling synergistically enhances the tumor suppressive role of triptolide in triple‑negative breast cancer cells

Wu,Hongyan; Sun,Ting; Bi,Rui

doi:10.3892/ol.2019.10356

Inhibition of insulin‑like growth factor 1 signaling synergistically enhances the tumor suppressive role of triptolide in triple‑negative breast cancer cells

Authors:
- Hongyan Wu
- Ting Sun
- Rui Bi
View Affiliations

Affiliations: Department of Pharmacy, Tangshan People's Hospital, Tangshan, Hebei 063001, P.R. China, Department of Clinical Pharmacology, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei 050011, P.R. China
Published online on: May 14, 2019 https://doi.org/10.3892/ol.2019.10356
Pages: 822-829

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triptolide (TPL) is an active extract from a Chinese herb, which has been used for centuries in China. TPL exhibits numerous bioactivities and pharmacological effects, including antitumor, anti‑inflammatory and immunosuppressive activities. However, previous studies have further revealed a multi‑target toxicity of TPL, including reproductive toxicity, hepatotoxicity and renal cytotoxicity. To validate the clinical benefit and reduce the risk of TPL application, studies have investigated the combination of TPL with other reagents to allow lower doses and decrease toxicity. The present study reported that TPL and the insulin‑like growth factor‑1 receptor (IGF1R) inhibitor AG1024synergistically inhibited cell proliferation and induced apoptosis in triple‑negative breast cancer cells. Overexpression of B‑cell lymphoma 2 partially reversed the TPL and AG1024‑induced increase in apoptosis. A similar synergistic effect was observed with a combination of AG1024 and cisplatin, a DNA damage inducer, in MDA‑MB‑231 cells. These results suggested that inhibition of IGF1R may sensitize triple‑negative breast cancer cells to DNA damage inducers. Using publicly available data from The Cancer Genome Atlas, an amplification and gain of copy number of IGF1R was observed in 38% of triple‑negative breast tumors (n=82), 26% of estrogen receptor (ER)‑negative tumors (n=174) and 10% of ER‑positive tumors (n=594). Similarly, a higher alteration frequency of IGF1R was identified in basal‑like breast tumors compared with luminal A/B‑like breast tumors. Overexpressed proteins associated with these alterations were revealed to be significantly enriched in multiple oncogenic signaling pathways, key transcription factor networks and DNA repair pathways. In summary, the present study suggested that inhibition of IGFR signaling and induction of DNA damage may exhibit synergistic effects for the treatment of triple‑negative and ER‑negative breast cancer.

View Figures

View References

1	Corson TW and Crews CM: Molecular understanding and modern application of traditional medicines: Triumphs and trials. Cell. 130:769–774. 2007. View Article : Google Scholar : PubMed/NCBI
2	Meng C, Zhu H, Song H, Wang Z, Huang G, Li D, Ma Z and Ma J, Qin Q, Sun X and Ma J: Targets and molecular mechanisms of triptolide in cancer therapy. Chin J Cancer Res. 26:622–626. 2014.PubMed/NCBI
3	Xiong J, Su T, Qu Z, Yang Q, Wang Y, Li J and Zhou S: Triptolide has anticancer and chemosensitization effects by down-regulating Akt activation through the MDM2/REST pathway in human breast cancer. Oncotarget. 7:23933–23946. 2016. View Article : Google Scholar : PubMed/NCBI
4	Cheng X, Shi W, Zhao C, Zhang D, Liang P, Wang G and Lu L: Triptolide sensitizes human breast cancer cells to tumor necrosis factor-α-induced apoptosis by inhibiting activation of the nuclear factor-κB pathway. Mol Med Rep. 13:3257–3264. 2016. View Article : Google Scholar : PubMed/NCBI
5	Ateba SB, Ngeu ST, Mvondo MA, Tchoumtchoua J, Awounfack CF, Krenn L and Njamen D: Natural terpenoids against female breast cancer: A 5-year recent research. Curr Med Chem. 25:3162–3213. 2018. View Article : Google Scholar : PubMed/NCBI
6	Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
7	Sims AH, Howell A, Howell SJ and Clarke RB: Origins of breast cancer subtypes and therapeutic implications. Nat Clin Pract Oncol. 4:516–525. 2007. View Article : Google Scholar : PubMed/NCBI
8	Peddi PF, Ellis MJ and Ma C: Molecular basis of triple negative breast cancer and implications for therapy. Int J Breast Cancer. 2012:2171852012. View Article : Google Scholar : PubMed/NCBI
9	Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, et al: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
10	Shao H, Ma J, Guo T and Hu R: Triptolide induces apoptosis of breast cancer cells via a mechanism associated with the Wnt/β-catenin signaling pathway. Exp Ther Med. 8:505–508. 2014. View Article : Google Scholar : PubMed/NCBI
11	Tan BJ, Tan BH and Chiu GN: Effect of triptolide on focal adhesion kinase and survival in MCF-7 breast cancer cells. Oncol Rep. 26:1315–1321. 2011.PubMed/NCBI
12	Yang A, Qin S, Schulte BA, Ethier SP, Tew KD and Wang GY: MYC inhibition depletes cancer stem-like cells in triple-negative breast cancer. Cancer Res. 77:6641–6650. 2017. View Article : Google Scholar : PubMed/NCBI
13	Tang Y, Wang J, Cheng J and Wang L: Antiestrogenic Activity of Triptolide in Human Breast Cancer Cells MDA-MB-231 and Immature Female Mouse. Drug Dev Res. 78:164–169. 2017. View Article : Google Scholar : PubMed/NCBI
14	Xi C, Peng S, Wu Z, Zhou Q and Zhou J: Toxicity of triptolide and the molecular mechanisms involved. Biomed Pharmacother. 90:531–541. 2017. View Article : Google Scholar : PubMed/NCBI
15	Li XJ, Jiang ZZ and Zhang LY: Triptolide: Progress on research in pharmacodynamics and toxicology. J Ethnopharmacol. 155:67–79. 2014. View Article : Google Scholar : PubMed/NCBI
16	Zhao H, Shi P, Deng M, Jiang Z, Li Y, Kannappan V, Wang W, Li P and Xu B: Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption. Oncotarget. 7:85515–85528. 2016. View Article : Google Scholar : PubMed/NCBI
17	Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ and Lee SJ: Synergistic cytotoxicity of BIIB021 with triptolide through suppression of PI3K/Akt/mTOR and NF-κB signal pathways in thyroid carcinoma cells. Biomed Pharmacother. 83:22–32. 2016. View Article : Google Scholar : PubMed/NCBI
18	Qiao Z, He M, He MU, Li W, Wang X, Wang Y, Kuai Q, Li C, Ren S and Yu Q: Synergistic antitumor activity of gemcitabine combined with triptolide in pancreatic cancer cells. Oncol Lett. 11:3527–3533. 2016. View Article : Google Scholar : PubMed/NCBI
19	Li H, Pan GF, Jiang ZZ, Yang J, Sun LX and Zhang LY: Triptolide inhibits human breast cancer MDA-MB-231 cell growth via downregulation of the ERα-mediated signaling pathway. Acta Pharmacol Sin. 36:606–613. 2015. View Article : Google Scholar : PubMed/NCBI
20	Peiró G, Adrover E, Sánchez-Tejada L, Lerma E, Planelles M, Sánchez-Payá J, Aranda FI, Giner D and Gutiérrez-Aviñó FJ: Increased insulin-like growth factor-1 receptor mRNA expression predicts poor survival in immunophenotypes of early breast carcinoma. Mod Pathol. 24:201–208. 2011. View Article : Google Scholar : PubMed/NCBI
21	Knowlden JM, Hutcheson IR, Barrow D, Gee JM and Nicholson RI: Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor. Endocrinology. 146:4609–4618. 2005. View Article : Google Scholar : PubMed/NCBI
22	Yamamoto K, Ichijo H and Korsmeyer SJ: BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol. 19:8469–8478. 1999. View Article : Google Scholar : PubMed/NCBI
23	Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et al: TCGA research network, perou cm. comprehensive molecular portraits of invasive lobular breast cancer. Cell. 163:506–519. 2015. View Article : Google Scholar : PubMed/NCBI
24	Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature. 90:61–70. 2012. View Article : Google Scholar
25	Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404. 2012. View Article : Google Scholar : PubMed/NCBI
26	Chen J, Bardes EE, Aronow BJ and Jegga AG: ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res 37(Web Server issue). W305–W311. 2009. View Article : Google Scholar
27	Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, van den Ouweland A, Merajver SD, Ethier SP and Schutte M: BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 1:. 66:41–45. 2006. View Article : Google Scholar
28	Wan CK, Wang C, Cheung HY, Yang M and Fong WF: Triptolide induces Bcl-2 cleavage and mitochondria dependent apoptosis in p53-deficient HL-60 cells. Cancer Lett. 241:31–41. 2006. View Article : Google Scholar : PubMed/NCBI
29	Chueh FS, Chen YL, Hsu SC, Yang JS, Hsueh SC, Ji BC, Lu HF and Chung JG: Triptolide induced DNA damage in A375.S2 human malignant melanoma cells is mediated via reduction of DNA repair genes. Oncol Rep. 29:613–618. 2013. View Article : Google Scholar : PubMed/NCBI
30	Davison Z, de Blacquière GE, Westley BR and May FEB: Insulin-like Growth Factor-Dependent Proliferation and Survival of Triple-Negative Breast Cancer Cells: Implications for Therapy. Neoplasia. 13:504–515. 2011. View Article : Google Scholar : PubMed/NCBI
31	Jeon JH, Kim SK, Kim HJ, Chang J, Ahn CM and Chang YS: Insulin-like growth factor-1 attenuates cisplatin-induced gammaH2AX formation and DNA double-strand breaks repair pathway in non-small cell lung cancer. Cancer Lett. 272:232–241. 2008. View Article : Google Scholar : PubMed/NCBI
32	Railo MJ, von Smitten K and Pekonen F: The prognostic value of insulin-like growth factor-I in breast cancer patients. Results of a follow-up study on 126 patients. Eur J Cancer 30A. 307–311. 1994. View Article : Google Scholar
33	Hartog H, Horlings HM, van der Vegt B, Kreike B, Ajouaou A, van de Vijver MJ, Marike Boezen H, de Bock GH, van der Graaf WT and Wesseling J: Divergent effects of insulin-like growth factor-1 receptor expression on prognosis of estrogen receptor positive versus triple negative invasive ductal breast carcinoma. Breast Cancer Res Treat. 129:725–736. 2011. View Article : Google Scholar : PubMed/NCBI
34	Martin JL and Baxter RC: Expression of insulin-like growth factor binding protein-2 by MCF-7 breast cancer cells is regulated through the phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway. Endocrinology. 148:2532–2541. 2007. View Article : Google Scholar : PubMed/NCBI
35	Zhang Y, Moerkens M, Ramaiahgari S, de Bont H, Price L, Meerman J and van de Water B: Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res. 13:R522011. View Article : Google Scholar : PubMed/NCBI
36	Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE and Nicholson RI: Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer. 11:793–814. 2004. View Article : Google Scholar : PubMed/NCBI
37	Riedemann J and Macaulay VM: IGF1R signalling and its inhibition. Endocr Relat Cancer. 13 (Suppl 1):S33–S43. 2006. View Article : Google Scholar : PubMed/NCBI